These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20738979)

  • 1. [Fondaparinux and lepirudin as therapeutic alternatives in a disseminated eczematous skin reaction to low-molecular-weight heparin].
    Santiago Sánchez-Mateos DI; Eguren C; de Argila D; Sánchez-Pérez J
    Actas Dermosifiliogr; 2010 Jul; 101(6):556-8. PubMed ID: 20738979
    [No Abstract]   [Full Text] [Related]  

  • 2. Type I and Type IV allergy to unfractionated heparin and low-molecular-weight heparin with no reaction to recombinant hirudin.
    Hallai N; Hughes TM; Stone N
    Contact Dermatitis; 2004 Sep; 51(3):153-4. PubMed ID: 15479209
    [No Abstract]   [Full Text] [Related]  

  • 3. Heparin-induced thrombocytopenia: comparison between response to fondaparinux and lepirudin.
    Al-Rossaies A; Alkharfy KM; Al-Ayoubi F; Al-Momen A
    Int J Clin Pharm; 2011 Dec; 33(6):997-1001. PubMed ID: 22002684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of heparin-induced thrombocytopenia with fondaparinux.
    Harenberg J; Jörg I; Fenyvesi T
    Haematologica; 2004 Aug; 89(8):1017-8. PubMed ID: 15339691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux.
    Hohenstein E; Tsakiris D; Bircher AJ
    Contact Dermatitis; 2004 Sep; 51(3):149-51. PubMed ID: 15479206
    [No Abstract]   [Full Text] [Related]  

  • 6. Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin.
    Schindewolf M; Ludwig RJ; Wolter M; Himsel A; Zgouras D; Kaufmann R; Boehncke WH; Lindhoff-Last E
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):378-80. PubMed ID: 18269612
    [No Abstract]   [Full Text] [Related]  

  • 7. [A study of 19 cases of allergy to heparins with positive skin testing].
    Phan C; Vial-Dupuy A; Autegarden JE; Amsler E; Gaouar H; Abuaf N; Pecquet C; Francès C; Soria A
    Ann Dermatol Venereol; 2014 Jan; 141(1):23-9. PubMed ID: 24461090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
    Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Müller MM; Kropff S; Lindhoff-Last E
    J Am Coll Cardiol; 2017 Nov; 70(21):2636-2648. PubMed ID: 29169470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy.
    Maetzke J; Hinrichs R; Staib G; Scharffetter-Kochanek K
    Allergy; 2004 Feb; 59(2):237-8. PubMed ID: 14763948
    [No Abstract]   [Full Text] [Related]  

  • 10. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases.
    Jappe U; Juschka U; Kuner N; Hausen BM; Krohn K
    Contact Dermatitis; 2004 Aug; 51(2):67-72. PubMed ID: 15373846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux.
    Koch P
    Contact Dermatitis; 2003 Dec; 49(6):276-80. PubMed ID: 15025697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.
    Grouzi E; Kyriakou E; Panagou I; Spiliotopoulou I
    Clin Appl Thromb Hemost; 2010 Dec; 16(6):663-7. PubMed ID: 19825921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
    Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
    Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance of Fondaparinux in Immediate-type Hypersensitivity to Heparins.
    Trog LM; Kahle B; Schindewolf M; Jappe U; Ludwig RJ
    Am J Med; 2015 Nov; 128(11):e21-2. PubMed ID: 26169891
    [No Abstract]   [Full Text] [Related]  

  • 15. Current anticoagulation options in percutaneous intervention: designing patient-specific strategies.
    French MH; Faxon DP
    Rev Cardiovasc Med; 2002; 3(4):176-82. PubMed ID: 12556751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heparin-induced thrombocytopenia].
    Cruz-González I; Sánchez-Ledesma M; Sánchez PL; Jang IK
    Rev Esp Cardiol; 2007 Oct; 60(10):1071-82. PubMed ID: 17953929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.
    Alsaleh KA; Al-Nasser SM; Bates SM; Patel A; Warkentin TE; Arnold DM
    Am J Hematol; 2008 Nov; 83(11):876-8. PubMed ID: 18803278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular-weight heparins: tolerance of a new recombinant hirudin.
    Koch P; Münssinger T; Rupp-John C; Uhl K
    J Am Acad Dermatol; 2000 Apr; 42(4):612-9. PubMed ID: 10727306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of heparin induced thrombocytopenia treated with lepirudin infusion: case report].
    Sünmez S; Okumuş G; Kiyan E; Ece T; Arseven O
    Tuberk Toraks; 2006; 54(2):185-8. PubMed ID: 16924578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia.
    Jolicoeur EM; Wang T; Lopes RD; Ohman EM
    Curr Cardiol Rep; 2007 Sep; 9(5):396-405. PubMed ID: 17877935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.